EP0804076A4 - Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents - Google Patents

Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents

Info

Publication number
EP0804076A4
EP0804076A4 EP95938753A EP95938753A EP0804076A4 EP 0804076 A4 EP0804076 A4 EP 0804076A4 EP 95938753 A EP95938753 A EP 95938753A EP 95938753 A EP95938753 A EP 95938753A EP 0804076 A4 EP0804076 A4 EP 0804076A4
Authority
EP
European Patent Office
Prior art keywords
adenoviruses
gene therapy
immunosuppressive agents
repeated administration
therapy involving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95938753A
Other languages
German (de)
French (fr)
Other versions
EP0804076A1 (en
Inventor
Bruce C Trapnell
Soonpin Yei
Alan Mcclelland
Michael Kaleko
Theodore Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Therapy Inc
Original Assignee
Genetic Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Therapy Inc filed Critical Genetic Therapy Inc
Publication of EP0804076A1 publication Critical patent/EP0804076A1/en
Publication of EP0804076A4 publication Critical patent/EP0804076A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95938753A 1994-10-19 1995-10-19 Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents Withdrawn EP0804076A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32567994A 1994-10-19 1994-10-19
US325679 1994-10-19
US47848295A 1995-06-07 1995-06-07
US478482 1995-06-07
PCT/US1995/013253 WO1996012406A1 (en) 1994-10-19 1995-10-19 Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents

Publications (2)

Publication Number Publication Date
EP0804076A1 EP0804076A1 (en) 1997-11-05
EP0804076A4 true EP0804076A4 (en) 1998-10-21

Family

ID=26985040

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95938753A Withdrawn EP0804076A4 (en) 1994-10-19 1995-10-19 Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents

Country Status (4)

Country Link
EP (1) EP0804076A4 (en)
JP (1) JPH10507758A (en)
CA (1) CA2200869A1 (en)
WO (1) WO1996012406A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
CA2213439A1 (en) * 1995-02-24 1996-08-29 The Trustees Of The University Of Pennsylvania Methods and compositions for administering gene therapy vectors
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
WO1997030167A1 (en) * 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
US6211160B1 (en) * 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
JP2001509168A (en) * 1997-01-29 2001-07-10 コーネル リサーチ ファウンデーション、インコーポレイティッド Multisite delivery of adenovirus vectors to induce angiogenesis
US5985824A (en) * 1997-02-27 1999-11-16 Genzyme Corporation Methods and compositions for treating cystic fibrosis
DE19711803A1 (en) * 1997-03-21 1998-09-24 Hoechst Ag Extension of expression of transgenic proteins by immunomodulating treatment with 15-deoxyspergualin
PL346796A1 (en) * 1998-09-21 2002-02-25 Genetics Inst Methods of downmodulating the immune response to therapeutic proteins
AU1915100A (en) * 1998-11-17 2000-06-05 Alkermes, Inc. A method of genetic vector delivery
CA2395544A1 (en) * 1999-12-28 2001-07-05 Novartis Ag Method of achieving persistent transgene expression
US20020014242A1 (en) 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
WO2003033520A2 (en) 2001-09-24 2003-04-24 University Of Pittburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diganostic methods and reagents
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2466431C (en) 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
SG166117A1 (en) * 2003-12-10 2010-11-29 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
AU2005336093B2 (en) 2004-10-08 2011-02-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Adoptive immunotherapy with enhanced T lymphocyte survival
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
WO2009073104A2 (en) 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38
JP5661476B2 (en) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Simian adenovirus SAdV-36, -42.1, -42.2 and -44 and their uses
WO2010011994A2 (en) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides and uses thereof
EP2774985B1 (en) 2008-10-31 2016-12-14 The Trustees Of The University Of Pennsylvania Simian adenovirus SAdV-43 and uses thereof
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
WO2012071318A2 (en) 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
US9265815B2 (en) 2011-04-29 2016-02-23 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
WO2013173702A2 (en) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
JP7028556B2 (en) 2013-05-03 2022-03-02 セレクタ バイオサイエンシーズ インコーポレーテッド Delivery of immunosuppressive agents with antigens for specific pharmacodynamic efficacy and induction of immune tolerance
JP6613231B2 (en) 2013-06-18 2019-11-27 ディーエヌエートリックス インコーポレイテッド Treatment of brain cancer with oncolytic adenovirus
MX2017002933A (en) 2014-09-07 2017-05-30 Selecta Biosciences Inc Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses.
CN109152342A (en) * 2016-05-12 2019-01-04 布赖恩.P.汉利 CRISPR and most of body cell of other gene therapy safe deliveries into human and animal
AU2018205496A1 (en) * 2017-01-07 2019-07-25 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US20200360453A1 (en) * 2019-04-28 2020-11-19 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507404A (en) * 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン How to treat infectious respiratory diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9612406A1 *

Also Published As

Publication number Publication date
EP0804076A1 (en) 1997-11-05
CA2200869A1 (en) 1996-05-02
WO1996012406A1 (en) 1996-05-02
JPH10507758A (en) 1998-07-28

Similar Documents

Publication Publication Date Title
EP0804076A4 (en) Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
EP0692975A4 (en) Administration of vaso-active agent and therapeutic agent
IL105914A0 (en) Methods and compositions for in vivo gene therapy
ZA958686B (en) Viral vectors and use in gene therapy
PL330814A1 (en) Compounds for and methods of delivering pharmaceutical preparations and their application
PL309686A1 (en) Nitrogen containing 6-member heteroaryl oxazolydinones and therapeutic agents containing them
PL334678A1 (en) Quinolinic and quinazolinic compounds useful in therapy in particular in that of bph
HUP0004326A3 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
GB9808840D0 (en) Treatment of depression and pharmaceutical preparations therefor
EP0960114A4 (en) Polymorphisms and new genes in the region of the human hemochromatosis gene
EP0971949A4 (en) Complexes and combinations of fetuin with therapeutic agents
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
GB9219425D0 (en) Therapeutic agent and its use
AU2668897A (en) Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
GB2294637B (en) Therapeutic compositions and methods of use
EP0959887A4 (en) Pharmaceutically active compounds and methods of use
ZA986047B (en) 6-pyrrolidin-2-ylpyrindines their preparation and their therapeutic application
EP1023076A4 (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
ZA951789B (en) Pharmaceutical materials and methods of administration
AU3053595A (en) Therapeutic treatment and preparations
EP1041986A4 (en) Pharmaceutically active compound and methods of use
GB9523066D0 (en) Compounds and their therapeutic use
EP1001966A4 (en) A senescence gene and its use in the treatment of cancer and other diseases
AU779514C (en) Methods and compositions for use in gene therapy for treatment of hemophilia
GB9525891D0 (en) Therapeutic agents and their preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970417

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980904

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020501